Author

Peter Waltman

Weill Cornell MedicineORCID 0009-0006-3142-6380Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Genetic & Genomic Medicine· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:variant calling· 1 Research Focus:variant effect prediction· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

Abigail S. KingiD· 2 shared Alicia AlonsoiD· 2 shared Andrea SboneriD· 2 shared Bhavneet BhinderiD· 2 shared David C. WilkesiD· 2 shared Juan Miguel MosqueraiD· 2 shared Jyothi ManohariD· 2 shared Kathryn GorskiiD· 2 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetic & Genomic Medicine

Abigail S. KingORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genetic & Genomic Medicinenpj Precision OncologyPeer-reviewedApr 21, 2026

EXaCT-2: An augmented and customizable oncology-focused whole exome sequencing platform

Peter Waltman, Pooja Chandra, Ken W. Eng…·Andrea Sboner

EXaCT-2 is a whole exome sequencing platform that detects various cancer-related genomic features with high accuracy and sensitivity, outperforming standard assays in detecting sub-clonal mutations and molecular metrics.

5 citationstop 2%

humanwhole-exome sequencing

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 10, 2025

Pan-Cancer PDOs Preserve Tumor Heterogeneity and Uncover Therapeutic Vulnerabilities

Hui–Hsuan Kuo, Bhavneet Bhinder, Hamza Numan Gokozan…·M. Laura Martín

This study develops a pan-cancer PDO platform to preserve tumor heterogeneity and identify therapeutic vulnerabilities, finding that 58% of PDOs respond to Talazoparib and combination screens reveal resistance-overcoming drugs.

DOI 10.1101/2025.04.10.647635

humanbulk RNA-seq

𝕏 PostBluesky